Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Interim analysis of a phase II study of the safety and efficacy of gentuzumab ozogamicin (Mylotarg) given in combination with cytarabine and daunorubicin in patients <60 years old with untreated acute myeloid leukemia

Interim analysis of a phase II study of the safety and efficacy of gentuzumab ozogamicin (Mylotarg) given in combination with cytarabine and daunorubicin in patients <60 years old with untreated acute myeloid leukemia. ASH. 2002.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.